This is our weekly round-up of expert information about the COVID-19 vaccines. The Conversation, a not-for-profit group, works with a wide range of academics across its global network to produce evidence-based analysis and insights. Get more regular updates from trusted experts by subscribing to our free newsletter .
This announcement underlines the likelihood that updated COVID-19 vaccines will be needed to handle variants such as P1 in the future. This variant is a particular concern as it carries the E484K mutation, which means it’s likely to be somewhat resistant to the vaccines currently available, says Simon Clarke, Associate Professor in Cellular Microbiology at the University of Reading. Other variants of concern are also present in Britain. B1525, also seen in Denmark and Nigeria, has been added to a global watch list of troubling viral variants. It also has the E484K mutation, as well as some other mutations and deletions to its genome, writes Sharon Peacock, Director of the COVID-19 Genomics UK Consortium (COG-UK). It’s thought that some of these might make this variant more infective. So far, there’s no way of telling what impact – if any – these and other variants are having on the effects of COVID-19 vaccines in the UK. Data on their effectiveness is only beginning to emerge. So far, it looks very positive: hospitalisations among vaccinated groups are down significantly. Still, studies of how well these vaccines are doing in the real world aren’t as rigorous as full clinical trials, so we should be cautious in how we interpret them, writes Mark Toshner, Lecturer in Translational Respiratory Medicine at the University of Cambridge. And, while it seems vaccines are having an impact on people developing severe disease in the UK, we still have very limited understanding on whether they stop people transmitting the virus. Indeed, no vaccine blocks 100% of people from being infected, says Deborah Fuller, Professor of Microbiology at the University of Washington. On top of this, the emerging variants could reduce the transmission-blocking potential of vaccines too. It’s very important we keep this in mind. A recent survey from the Office for National Statistics found that more than 40% of over-80s had broken lockdown rules after receiving their second COVID-19 vaccine dose. This suggests the potential risk of still being able to transmit the virus after being vaccinated is either widely misunderstood or else being ignored.
Get the latest news and advice on COVID-19, direct from the experts in your inbox. Join hundreds of thousands who trust experts by subscribing to our newsletter. vaccine testing clinical trials antibodies coronavirus covid-19 spread lockdown transmission uk
- FDA Halts J&J COVID-19 Vaccine Manufacturing at Emergent BioSolutions That Had Contamination Issue April 19, 2021
- EU Purchases 100M More Doses of Pfizer/BioNTech COVID-19 Vaccine April 19, 2021
- 5 Top Weekly TSXV Stocks: ReconAfrica Jumps Over 100 Percent April 19, 2021
- Trip.com first global travel group to list on HKSE, NASDAQ April 19, 2021
- Dollar Slide Extends April 19, 2021